Bio Essence swings to Q2 FY26 profit of $270,077; revenue more than doubles to $794,711

• Bio Essence posted net income of $475,450 for the six months ended June 30, 2026, swinging from a loss a year earlier.
• Revenue climbed to $1.3 million, up 360.43% year over year, driven by higher OEM service orders including large orders from two new customers.
• General and administrative costs edged down 3.07% to $293,849, while selling expense fell 97.73% to $680.
• Operating cash flow turned to an outflow of $352,320, while cash and equivalents were $675 at quarter-end with a 0.38:1 current ratio.
• Separately, it issued 7,000,000 shares valued at $3.5 million to buy MediFlow AI software, while accruing about $1.5 million for a lease dispute.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio Essence Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090174), on August 14, 2026, and is solely responsible for the information contained therein.